Chelation Therapy Coverage Criteria
Customize your policy alerts
Sign up for all priority health policy alerts
Know when priority health releases new policies or updates existing guidance.
Monitor payer policy activity
Establishes Priority Health coverage criteria, applicable diagnoses, documentation, coding, and prior authorization considerations for chelation therapy; applies to Priority Health members and providers delivering care under covered plans.
Added additional non-covered conditions for chelation therapy.
New Policy Scope section was added.
New FDA/Regulatory section was added.
New Medical/Professional Society Guidelines section was added.
Policy structure clarified.
Coverage Criteria for Chelation Therapy
Medically Necessary Indications
Chelation therapy is medically necessary when used to treat ALL of the following diagnoses as listed:
Medically necessary diagnoses
- Included diagnoses: a. Biliary cirrhosis; b. Cooley's anemia; c. Cystinuria; d. Heavy metal poisoning (e.g., arsenic, copper, gold, iron, lead, mercury); e. Wilson's disease; f. Patients who have iron overload secondary to multiple blood transfusions (e.g., sickle cell anemia)
Each listed diagnosis is an acceptable indication
Not Medically Necessary
Chelation therapy is considered not medically necessary when used to treat the following conditions:
Not medically necessary
- Examples: Autism Spectrum Disorders; Cardiovascular disease (including atherosclerosis, coronary artery disease); Neurodegenerative disorders (Alzheimer's disease or other dementias); Stroke
List is not exhaustive
Coverage for chelation therapy is contingent on the member's specific benefits and the applicable plan documents. Group-specific policy or state‑mandated plan documents will supersede this medical policy when applicable. For self‑funded (ASO), individual, HMO/EPO, POS, PPO, Medicare, and Medicaid/Healthy Michigan Plan products, providers should consult the applicable plan or product documents for final coverage determinations; when discrepancies exist, the plan or program rules govern. Providers seeking prior authorization must follow the procedures in the Priority Health Provider Manual and submit documentation demonstrating medical necessity when prior authorization is required.
The literature and guideline commentaries flag the use of chelation therapy for Autism Spectrum Disorder and for treatment of alleged mercury poisoning without appropriate diagnostic evaluation as unsupported and potentially harmful. Choosing Wisely and specialty toxicology guidance specifically caution against chelation except for documented metal intoxication diagnosed by validated testing, and reviews of autism-related chelation trials note poor quality evidence and safety concerns.
Use of chelation therapy to treat Autism Spectrum Disorder is not supported by quality evidence and is considered not medically necessary. Professional organizations and systematic reviews advise against routine testing or chelation for autistic behaviors; published case reports and series also document serious adverse events associated with inappropriate chelation in children.
Chelation therapy for atherosclerotic cardiovascular disease and for neurodegenerative disorders (including Alzheimer's disease) is not proven to improve clinical outcomes in routine practice and is considered not medically necessary. Large trials and systematic reviews (including TACT and TACT2 and multiple reviews) did not demonstrate consistent benefit across populations; some subgroup findings were not replicated and more high‑quality evidence is required before routine use can be recommended.
Sources cited in this policy identify chelation for Autism Spectrum Disorder and for unproven claims of mercury poisoning as unsupported and potentially inappropriate. Toxicology and clinical practice guidance emphasize that chelating agents should be reserved for documented heavy metal intoxication confirmed by validated biological testing, and that use for unverified mercury exposure or other non‑evidence‑based indications may prompt denial of coverage or safety concerns.
Relevant Coding
| D56.0 - D56.9 | Thalassemia |
| D57.00 - D57.819 | Sickle-cell disorders |
| E72.00 - E72.09 | Disorders of amino-acid transport |
| E83.00 - E83.09 | Disorders of copper metabolism |
| E83.10 - E83.19 | Disorders of iron metabolism |
| E83.52 | Hypercalcemia |
| K74.3 | Primary biliary cirrhosis |
| K74.4 | Secondary biliary cirrhosis |
| K74.5 | Biliary cirrhosis, unspecified |
| T56.0x1A - T56.0x4S | Toxic effects of lead and its compounds |
| J0470 | Injection, dimercaprol, per 100 mg. |
| J0600 | Injection, edetate calcium disodium, up to 1000 mg. |
| J0895 | Injection, deferoxamine mesylate, 500 mg. |
| J3520 | Edetate disodium, per 150 mg (not covered for Medicaid) |
| S9355 | Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem requires prior auth |
Provider Actions, Prior Authorization & Documentation
Stepwise chelation for iron overload
For iron overload (transfusional or secondary), clinicians should follow a stepwise approach using guideline‑recommended iron chelators. Initiation, selection, and modification of therapy should be based on established indications, iron burden measures, tolerability, and response. Prior authorization and documentation requirements still apply for individual agents or combination regimens.
- Preferred agents: deferoxamine, deferiprone, deferasirox (select according to age, formulation availability, and adverse-effect profile).
- Start with monotherapy using an evidence‑based agent appropriate for the patient; escalate to alternative single agents if ineffective or not tolerated.
- Consider combination regimens (e.g., deferasirox + deferoxamine or deferiprone + deferoxamine) for patients with inadequate response to monotherapy or severe iron burden, supported by clinical evidence.
- Document baseline iron burden (e.g., serum ferritin trends, liver iron concentration by MRI) and clinical rationale for switching or adding agents.
- Monitor for drug-specific adverse effects (e.g., agranulocytosis with deferiprone; renal/hepatic toxicity with deferasirox; infusion‑related issues with deferoxamine) and provide laboratory surveillance per product labeling.
- Provide evidence of prior trials of guideline‑recommended therapy when requesting individual case review or authorization for combination therapy or off‑label regimens.
Definitions and Protocols
Background and Evidence Summary
Chelation refers to administration of agents such as EDTA, DMSA, or DMPS to bind metals and enhance urinary excretion. A commonly cited EDTA regimen involves repeated intravenous infusions—typically a series of approximately 30 infusions of 3 g disodium EDTA with adjunctive vitamins, minerals, and supportive agents delivered over 1.5–3 hours in 500–1000 mL saline, often on a weekly or biweekly schedule. Evidence supports chelation for documented heavy metal intoxication and selected hematologic or genetic conditions that cause iron or copper overload, whereas proposed uses outside these indications lack robust evidence.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.